
HALO: | Fused-Core® Particle Technology

Application Note: 154-PR

Effect of Acid Modifiers on Intact mAb Peak Shape



TEST CONDITIONS:

Column: HALO 1000Å C4, 2.7µm, 2.1 x 150 mm

Part Number: 92712-714

Mobile Phase:

A= Water, with 0.1% FA, DFA, or TFA as noted

B= 80/20 ACN/Water, with 0.1% FA, DFA, or TFA as noted

Gradient:

Time (min.) %В 0.00 35.0 12.00 47.5

Flow Rate: 0.4 mL/min Initial Pressure: 218 bar Temperature: 80 °C Injection Volume: 2 μL

Sample Solvent: 30/70 ACN/Water Detection: UV 280 nm, PDA

Data Rate: 12.5 Hz Response Time: 0.05 sec

Flow Cell: 1 uL

LC System: Shimadzu Nexera X2

STRUCTURES:

Trastuzumab (~148 kDa) is a monoclonal antibody (mAb) used to treat breast cancer. TFA and DFA can be used as mobile phase additives instead of formic acid to provide much

narrower and more symmetrical peaks, and to allow

adjustments to retention and resolution among minor variants.



FOR MORE INFORMATION OR TO PLACE AN ORDER, CONTACT: